Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	244	3q13.31	TIGIT	T cell immunoreceptor with Ig and ITIM domains	3
Mouse	1	249	16 B4	Tigit	T cell immunoreceptor with Ig and ITIM domains
Rat	-	-	11q21	Tigit	T cell immunoreceptor with Ig and ITIM domains

Previous and Unofficial Names

T-cell immunoreceptor with Ig and ITIM domains | V-set and immunoglobulin domain containing 9 | V-set and transmembrane domain containing 3 | VSIG9 | VSTM3 | WUCAM [1]

Database Links
Alphafold	Q495A1 (Hs), P86176 (Mm)
CATH/Gene3D	2.60.40.10
ChEMBL Target	CHEMBL4630878 (Hs)
Ensembl Gene	ENSG00000181847 (Hs), ENSMUSG00000071552 (Mm), ENSRNOG00000056574 (Rn)
Entrez Gene	201633 (Hs), 100043314 (Mm), 363784 (Rn)
Human Protein Atlas	ENSG00000181847 (Hs)
KEGG Gene	hsa:201633 (Hs), mmu:100043314 (Mm), rno:363784 (Rn)
OMIM	612859 (Hs)
Pharos	Q495A1 (Hs)
RefSeq Nucleotide	NM_173799 (Hs), NM_001146325 (Mm)
RefSeq Protein	NP_776160 (Hs), NP_001139797 (Mm)
UniProtKB	Q495A1 (Hs), P86176 (Mm)
Wikipedia	TIGIT (Hs)

Immunopharmacology Comments

TIGIT is now considered as an alternate inhibitory immune checkpoint protein which may have potential immunotherapeutic potential, particularly in conditions refractory to more established PD-1 checkpoint inhibition. Given its presence on T cells and NK cells, TIGIT offers an intervention point for targeting both the adaptive and innate arms of the immune system. Clinical development of anti-TIGIT monoclonal antibodies is in preliminary stages. Combination therapies with existing immune checkpoint inhibitors are considered particularly promising. MTIG7192A (NCT02794571; ± anti-PD-L1 atezolizumab) and BMS-986207 (NCT02913313; ± anti-PD-1 nivolumab) are two early phase potential immuno-oncology mAbs that prevent TIGIT-PVR interaction. OncoMed and Merck also have anti-TIGIT antibodies in their immuno-oncology pipelines (OMP-313M32/etigilimab and MK-7684 respectively).

Cell Type Associations

Immuno Cell Type:  Innate lymphoid cells Cell Ontology Term:   group 1 innate lymphoid cell (CL:0001067) group 3 innate lymphoid cell (CL:0001071) Comment:  TIGIT is expressed by human ILC1s and ILC3s. References:  2

Immuno Cell Type:  Natural killer cells References:  2-3

Immuno Cell Type:  T cells Comment:  Expressed on regulatory, memory and activated T cells. References:  3

Immuno Process Associations

Immuno Process:  T cell (activation)

Immuno Process:  Immune regulation

Immuno Process:  Cytokine production & signalling

Immuno Process:  Chemotaxis & migration

Immuno Process:  Cellular signalling

General Comments

TIGIT was originally identified as a high affinity binding partner of the poliovirus receptor (PVR; P15151). TIGIT-PVR interaction promotes the generation of mature immunoregulatory dendritic cells and leads to suppression of T cell activation. The TIGIT protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590.